Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 27-31

  Cass, Ilana ^a   Walts, Ann ^b   Karlan, Beth Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cedars Sinai Medical Center   (United States)

Author keywords

BRCA; Risk Reducing Surgery

Indexed keywords

ADULT; AGED; ARTICLE; BILATERAL SALPINGOOOPHORECTOMY; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HYSTERECTOMY; ONCOGENE; PATHOLOGIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SALPINGOOOPHORECTOMY; UTERINE TUBE; UTERUS CAVITY;

ADULT; AGED; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77949289465     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.023     Document Type: Article

References (45)

1. Ford D., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 3 (1998) 676-689
2. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
3. Antoniou A., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 5 (2003) 1117-1130
4. Satagopan J.M., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res. 8 12 (2002) 3776-3781
5. Cass I., et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet. Gynecol. 106 6 (2005) 1327-1334
6. Aziz S., et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol. Oncol. 80 (2001) 341-345
7. Levine D.A., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. 21 22 (2003) 4222-4227
8. Brose M.S., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl. Cancer Inst. 94 18 (2002) 1365-1372
9. Rebbeck T.R., Kauff N.D., and Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 101 2 (2009) 80-87
10. Colgan T.J., et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25 10 (2001) 1283-1289
11. Callahan M.J., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 25 25 (2007) 3985-3990
12. Powell C.B., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23 1 (2005) 127-132
13. Carcangiu M.L., et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am. J. Surg. Pathol. 30 10 (2006) 1222-1230
14. Salazar H., et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. 88 24 (1996) 1810-1820
15. Lu K.H., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 14 (2000) 2728-2732
16. Leeper K., et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 1 (2002) 52-56
17. Rebbeck T.R., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 21 (2002) 1616-1622
18. Meeuwissen P.A., et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol. Oncol. 97 2 (2005) 476-482
19. Hermsen B.B., et al. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J. Clin. Oncol. 25 11 (2007) 1383-1389
20. Olivier R.I., et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol. Oncol. 100 1 (2006) 20-26
21. Finch A., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Jama 296 2 (2006) 185-192
22. Kauff N.D., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 21 (2002) 1609-1615
23. Crum C.P., et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19 1 (2007) 3-9
24. Medeiros F., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 2 (2006) 230-236
25. Guillem J.G., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. 24 28 (2006) 4642-4660
26. Lewin S.a.K., and Noah G. Risk-reducing salpingo-oophorectomy for the prevention of inherited breast and ovarian cancer. In: Lu K.H. (Ed). Hereditary Gynecologic Cancer: Risk, prevention and management (2008), informa healthcare, New York
27. Sternberg S. Histology for pathologists. 2nd ed. (1997), Lippincott-Raven, New York 918-920
28. Lee Y., et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol. 13 1 (2006) 1-7
29. Gerritzen L.H., et al. A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy. Int. J. Gynecol. Cancer 16 5 (2006) 1940-1944
30. Piek J.M., et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195 4 (2001) 451-456
31. Michon G. Final answers: Perimeter of an ellipse. Numericana Volume (2009)
32. Kindelberger D.W., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31 2 (2007) 161-169
33. Crum C.P., et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 5 1 (2007) 35-44
34. Podratz K.C., et al. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 154 6 (1986) 1319-1326
35. Alvarado-Cabrero I., et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol. Oncol. 72 3 (1999) 367-379
36. Kauff N.D., and Barakat R.R. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J. Clin. Oncol. 25 20 (2007) 2921-2927
37. Piver M.S., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 9 (1993) 2751-2755
38. Chen K.T., Schooley J.L., and Flam M.S. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet. Gynecol. 66 3 Suppl (1985) 93S-94S
39. Lavie O., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol. Oncol. 92 2 (2004) 521-524
40. Karlan B. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol. Oncol. 92 (2004) 519-520
41. Biron-Shental T., et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur. J. Surg. Oncol. 32 10 (2006) 1097-1100
42. Levine D.A., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 3 (2001) 395-398
43. Goshen R., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome. Gynecol. Oncol. 79 3 (2000) 477-481
44. Beiner M.E., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol. Oncol. 104 1 (2007) 7-10
45. Lu K.H., and Kauff N.D. Does a BRCA mutation plus tamoxifen equal hysterectomy. Gynecol. Oncol. 104 1 (2007) 3-4